« US R&D tax credit: SOCMA to Me | Main | Amgen in Acquisitive Mood? »



TrackBack URL for this entry:

Listed below are links to weblogs that reference Anjan Selz Takes SWOT at Biosimilar Market:


Feed You can follow this conversation by subscribing to the comment feed for this post.


My colleagues and I have authored what we believe is India’s first ever complete mapping of the Biosimilars opportunity in India. The report is nowbeing made available to the general public.
Various issues have been dealt with, such as:
- Patent expirations
- Regulatory frameworks
- Infrastructure Requirements
- Etc.
If anyone is interested in this report, please contact me at (infoalcpl AT gmail DOT com), and I would send you the brochure and other details.


The Pharmalot blog reports that the FDA will be holding a two day seminar on biosimilars on Nov 2nd and 3rd in Silver Spring, MD.
The meeting is the latest signal that the FDA is formulating a policy toward approving biosimilars, a topic that greatly concerns drugmakers, insurers, doctors, investors and policymakers, among many others, given the potential for huge disparities in price between brand-name meds and copycats. The move comes after Congress earlier this year gave the FDA a green light to approve biosimilars

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC

visited 6 states (46.1%)
Create your own visited map of Canada